Key result
Phosphodiesterase 5 inhibitors dilate the large epicardial coronary artery and selectively lower pulmonary arterial pressure in animal models, suggesting potential utility for cardiovascular diseases.
Why the study?
Do PDE 5 inhibitors improve hemodynamic parameters in animal models of cardiovascular disease?
Do PDE 5 inhibitors improve hemodynamic parameters in animal models of cardiovascular disease?
Preclinical evidence suggests PDE 5 inhibitors may be a promising therapeutic avenue for heart failure, pulmonary hypertension, and angina by modulating cGMP levels in vascular smooth muscle.
Answers are grounded in this paper and cite their sources.
Supports exploration of PDE5 inhibitors for HF and PH; leaves open translation from animal models to clinical practice.
Phosphodiesterase 5 (PDE 5), which is actually a family of PDE isozymes, hydrolyses cGMP with a high degree of selectivity and is insensitive to calmodulin (CaM). PDE 5 has been identified in the aorta, mesenteric or pulmonary arteries and saphenous vein, suggesting that it plays an important role in the regulation of cGMP levels in vascular smooth muscle, much like stimulators of cGMP synthesis, such as endothelium-derived relaxing factor (EDRF) and atrial natriuretic peptide (ANP). Several selective and potent PDE 5 inhibitors, which can be used to determine the pharmacological effects on cardiovascular diseases, have been synthesised by various pharmaceutical companies and are currently being studied. Results have shown that these PDE 5 inhibitors dilate the large epicardial coronary artery in conscious pigs and selectively lower the pulmonary arterial pressure in animal models of congestive heart failure or pulmonary hypertension, suggesting that these inhibitors may be useful as a therapy for heart failure, pulmonary hypertension, and angina. It is likely that the therapeutic benefit of PDE 5 inhibitors will be assessed in the near future.
No takes yet. Share an insight, caveat, or question.
Saeki et al. (1996) conducted a review in Cardiovascular diseases (heart failure, pulmonary hypertension, angina). Phosphodiesterase 5 (PDE 5) inhibitors was evaluated. Phosphodiesterase 5 inhibitors dilate the large epicardial coronary artery and selectively lower pulmonary arterial pressure in animal models, suggesting potential utility for cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: